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ÖZET
Amaç: Bu çalışmada metastazı olmayan meme kanserli 
hastalarda idrar piridinolin, deoksipiridinolin ve serum al-
kalen fosfataz düzeyleri ölçüldü ve 6 yıllık takipte kemik 
metastazının biyokimyasal belirteçleri olarak idrar piridi-
nolin ve deoksipiridinolinin rolü değerlendirildi.
Gereç ve yöntem: Çalışma kemik metastazı olmayan 34 
hasta ve kontrol grubu olarak 40 sağlıklı bireyi içermek-
tedir.
Bulgular: Serum ALP hariç idrar piridinolin ve deoksipi-
ridinolin düzeyleri kemik metastazı olmayan hastalarda 
kontrol grubundan belirgin olarak yüksekti. 6 yıllık takip 
sonucunda  hastaların  %20.5’da  metastaz  olduğu  belir-
lendi. Metastaz tiplerinin dağılımı: %2.9 lokal, %2.9 kara-
ciğer, %5.9 akciğer ve %8.8 kemik metastazı. Piridinolin 
için 43 pmol/ µmol kreatinin cut off değerinin sensitiivtesi 
%82 ve spesifitesi %80 olarak belirlendi. Deoksipiridinolin 
için 9.53 pmol/ µmol kreatinin cut off değerinin sensitiivte-
si %76 ve spesifitesi %72 olarak belirlendi.
Sonuç: Bu çalışma idrar çapraz bağlarının ölçümünün 
meme kanserinde kemiğe metastatik yayılımın erken be-
lirlenmesine katkıda bulunabileceğini gösterdi. Ancak ge-
niş ölçekli gruplarla ileri çalışmalar yapılmalıdır.
Anahtar kelimeler: Meme kanserleri, kemik metastazla-
rı, deoksipiridinolin, piridinolin.
ABSTRACT
Objective: In this study, urinary pyridinoline (uPYR), uri-
nary deoxypyridinoline (uDPD) and serum alkaline phos-
phatase (sALP) levels were measured in patients without 
metastatic breast cancer and the role of uPYR and uDPD 
as biochemical markers of bone metastases were exam-
ined during a six years follow-up. 
Materials and methods: Totally, 34 patients without bone 
metastasis and 40 healthy individuals as a control group 
were included in the study.
Results: Urinary pyridinoline and uDPD levels were sig-
nificantly higher in patients without bone metastasis than 
in  normal  controls  (p<0,05),  except  sALP  levels. As  a 
result of a 6-year follow-up of patients, 20.5% had me-
tastasis. The distribution of metastasis types was as fol-
lows: 2.9% of those patients had local, 2.9% had liver, 
5.9% had lung and 8.8% had bone metastasis. The cut off 
value, sensitivity and specifity of uPYR was established 
as 47,3 pmol/µmol creatinin, 82% and 80% respectively. 
The cut off value, sensitivity and specifity of uDPD were 
determined as 9.53 pmol/µmol creatinin, 76%, 72% re-
spectively.
Conclusions:  This  study  demonstrated  that  measure-
ment of urinary collagen cross-links assay may contrib-
ute to the early detection of metastatic spread to bone in 
breast cancer. However further studies with larger scaled 
groups should be performed. J Clin Exp Invest 2011; 2 
(4): 420-424
Key words: Breast neoplasms, bone metastases, deoxy-
pyridinoline, pyridinoline
INTRODUCTION
Breast cancer is the cancer of breast tissue. World-
wide, it is the most common form of cancer in fe-
males, affecting approximately 1 out of 11-12 wom-
en at some stage of their life in the Western world. 
Although  significant  efforts  are  made  to  achieve 
early detection and effective treatment, about 20% 
of all women with breast cancer will die from the Z. Giniş et al. Urinary pyridinoline in breast cancer 421
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disease, and it is the second most common cause 
of cancer deaths in women.1
Up to one-third of patients with early stage breast 
cancer  will  eventually  die  from  the  disease,  and 
most of these (~80%) will have bone metastases.2,3 
Although a majority of these bone metastases are 
destructive  or  osteolytic,  a  significant  percentage 
also  causes  abnormal  bone  formation  or  osteo-
sclerotic lesions. Once tumor has metastasized to 
bone, the disease is incurable. Because the aver-
age survival of breast cancer patients following di-
agnosis of bone metastases is 24–36 months, the 
morbidity of bone pain, fracture, hypercalcemia and 
nerve  compression  syndromes  are  longstanding. 
Therapeutics to treat and prevent these devastating 
complications of bone metastases are therefore in 
great demand.4
The  metastases  to  bone  causes  accelerated 
bone resorption both from direct effects of the tumor 
itself and through the activation of osteoclast cells in 
bone via humoral and growth factors such as cytok-
ines, platelet-derived growth factor and parathyroid-
related protein.5
Breast  cancer  may  affect  bone  metabolism, 
producing increased bone resorption with or with-
out an associated increase in bone formation. Bone 
metastases usually stimulate bone resorption more 
than bone formation and thus markers of bone for-
mation, e.g. alkaline phosphatase, are not as valu-
able markers of disease activity as markers of bone 
degradation  such  as  urinary  pyridinoline  (uPYR) 
and urinary deoxypyridinoline (uDPD).6
uPYR  and  uDPD  is  formed  during  the  post-
translational  phase  of  collagen  synthesis  and  is 
corporated into the bone matrix as a component of 
collagen molecules. Whereas uPYR is widely dis-
tributed throughout the body tissues, uDPD is only 
found in collagen of bone and dentin.7,8
When bone resorption occurs, osteoclastic deg-
radation of bone matrix releases uPYR and uDPD 
into the circulation; these compounds are than ex-
creted in urine. Measurement of urinary elimination 
of these compounds may provide useful information 
on the change of bone resorption.9
In this study, we measured uPYR and uDPD in 
patients without metastatic breast cancer and ex-
amined the role of uPYR and uDPD as biochemi-
cal markers of bone metastases. We compared the 
results of urine uPYR, uDPD and serum alkaline 
phosphatase (sALP) with breast cancer cases with 
no known bone metastases, with control subjects. 
And patients were followed for six years. Further-
more, the effect of menopause was investigated on 
levels of urine uPYR, uDPD and sALP.
MATERIALS AND METHODS
Patients and study design
As shown in Table I, thirty-four patients with histo-
logically verified breast cancer without bone metas-
tasis and 40 age- and menapausal-matched healthy 
control  participated  in  the  investigation.  Healthy 
control subjects were ambulatory population with-
out evidence of neoplastic or metabolic disease.
Patients with skeletal, endocrine, hepatic dis-
ease or with previous medical conditions or drug 
terapies that may affect bone metabolism were ex-
cluded from this study. Based on clinical, radiologi-
cal and sintigraphic evidence, patients without met-
astatic breast cancer were selected for this study. 
All patients were referred from newly diagnosed and 
not receiving any treatment patient groups.
Written  informed  consent  was  obtained  from 
both  healthy  controls  and  cancer  patients  before 
the collection of blood or urinary samples. The study 
was approved by the local ethics committee.
Sample collection and assays
Urine sample for measurement of uPYR, uDPD and 
creatinine was collected between 10:00 a.m. and 
12:00  a.m.,  from  fasting  individuals.  Specimens 
were divided into two aliquots, and urinary concen-
trations of creatinine were measured immediately 
after sample collection by standard laboratory meth-
ods using an autoanalyzer (Abbott, Aeroset - Texas, 
USA). The other aliquot was stored at -20°C until 
analyzed. 
uPYR and uDPD were assayed by automated 
HPLC  measurements  was  supplied  by  Chromos-
ystems Instruments and Chemical GmbH, Munich, 
Germany. The intra-assay coefficients of variation 
for uPYR and uDPD were 3,8% and 5,9%, respec-
tively, and for inter-assay variation were 5,1% and 
8,9%, respectively. The values obtained were cor-
rected for creatinine excretion and the data were 
expressed pmol PYR (or DPD) per µmol creatinin. 
Blood samples for measurement of sALP were 
collected from patients who had fasted overnight, 
centrifuged  and  assayed  by  standard  laboratory 
methods (Abbott, Aeroset - Texas, USA)
Statistical analysis
Results  having  normal  distribution  are  reported 
as mean ± SD. Kolmogorov-Smirnov was used to Z. Giniş et al. Urinary pyridinoline in breast cancer 422
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check the normal distribution of all parameters. The 
statistical  significance  of  the  differences  between 
the means of uDPD/Cre, u uPYR /Cre ratios and 
sALP of premenopausal and postmenopausal pa-
tients without bone metastases and healthy controls 
were assessed by Mann-Whitney U test. The sta-
tistical significance of the differences between the 
means of uDPD/Cre, uPYR/Cre ratios and sALP of 
patients and control groups was assessed by Inde-
pendent Student’s T test. Values of p less than 0.05 
were considered as significant. The ROC curve was 
used to evaluate the diagnostic values of the pa-
rameters 
RESULTS
In  patients  without  bone  metastases  and  healthy 
controls, uDPD/Cre, uPYR /Cre ratios and sALP did 
not  differ  in  premenopausal  and  postmenopausal 
patients (p>0,05) (Table 1).
Table 1. Age and laboratory parameters in normal controls and cancer patients according to menopausal status
Controls Patients
Premenopausal
 n=25
Postmenopausal
 n=15
P
Premenopausal
 n=12
Postmenopausal
 n=22
P
Age, years 34±6.3 55±5.4 <0.05 41±9.8 61±8.9 <0.05
uPYR (pmol/µmol) 40.17±1.91 38.75±1.92 >0.05 59.83±4.88 60.78±4.25 >0.05
uDPD (pmol/µmol) 9.59±0.63 8.86±0.61 >0.05 13.82±1.37 13.36±0.90 >0.05
sALP (U/L) 30.62±1.57 27.19±1.42 >0.05 21.76±3.11 27.90±2.74 >0.05
uPYR and uDPD levels were significantly high-
er in patients without bone metastases than in nor-
mal controls (p<0,05). But In patients without bone 
metastases and healthy controls sALP did not differ 
(Table 2).
Table 2. Urinary pyridinoline/creatinin and deoxypyridino-
line/creatinin and serum alkaline phosphatase levels in 
patients without bone metastases and healthy controls
Patients
 (n=34)
Controls
 (n=40)
p
Urinary pyridinoline/
Creatinin (pmol/µmol) 60.45± 18.68 39.64±8.75 <0.001
Urinary deoxypyridinoline/
Creatinin (pmol/µmol)
13.532±4.35 9.31±2.91 <0.001
Serum alkaline
 phosphatase (IU/L)
25.73±12.38 29.33±7.20 NS
NS: Not significant
After a 6-year follow-up of patients, 5.9% had 
died (n=2), 20.5% metastasis patients are alive yet. 
The distribution of metastasis types were as follows: 
2.9% of those patients local (n=1), 2.9% liver (n=1), 
5.9% lung (n=2) and 8.8% bone metastasis (n=3).
The  cut  off  value,  sensitivity  and  specifity  of 
uPYR were established 47,3 pmol/µmol creatinin, 
82% and 80% respectively. The cut off value, sen-
sitivity and specifity of uDPD were determined 9,53 
pmol/µmol creatinin, 76%, 72% respectively. Area 
under the curve of uPYR, uDPD and sALP were 
found 0.84, 0.79 and 0.35 respectively (Figure 1).
Figure  1.  Receiver  operating  characteristic  curves  of 
uPYR, uDPD and sALP in the diagnosis of bone metas-
tasis.
DISCUSSION
Bone metastasis is present in 69% of patients with 
terminal breast cancer. It is often difficult to detect 
early bone metastasis and to assess their therapeu-Z. Giniş et al. Urinary pyridinoline in breast cancer 423
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tic responses solely based on bone scans and bone 
x-rays.9
In this study, we measured urine uPYR, uDPD 
and sALP in patients without metastatic breast can-
cer and examined the role of uPYR and uDPD as a 
biochemical marker of bone metastasis. We com-
pared the levels of uPYR and uDPD and sALP with 
breast cancer cases with no known bone metasta-
sis, and a group of control subjects. Furthermore, 
the effect of menopause was investigated on lev-
els of uPYR, uDPD and sALP and all patients were 
followed-up for six years.
Bone metastasis usually stimulate bone resorp-
tion more than bone formation and thus markers of 
bone formation, e.g. alkaline phosphatase (except 
prostat cancers), are not as valuable markers of dis-
ease activity as markers of bone degredation such 
as uPYR and uDPD. Some researchers has report-
ed that the sensitivity of markers of bone resorp-
tion was 50-80%.6,10 Bombardieri et all. showed that 
sALP was not as valuable markers of disease activ-
ity as markers of bone degradation in their study.11
Several works have shown that assays of uPYR 
and uDPD may be valuable markers of bone resorp-
tion in a small series of patients with bone metasta-
sis. Hiraide et al. and Walne et al. have reported 
elevated  values  of  uPYR  and  uDPD  in  patients 
with bone metastasis compared with normal control 
groups.12,13 In this study, the uPYR and uDPD val-
ues for patients without bone metastasis were sig-
nificantly higher than those of healthy women.
The effect of menopause on uPYR and uDPD 
has been assessed by several studies. Uebelhart 
et al.14 showed that a significiant increase of uPYR 
and uDPD in postmenopausal healthy women com-
pared to age-matched premenopausal women. Hi-
raide et al.12 also showed significiantly higher values 
after menopause. According to these results, meno-
pause effect should be taken into account in the 
diagnosis of bone metastasis by uPYR and uDPD 
analysis. 
Although  age-related  changes  of  uPYR  and 
uDPD values were noted in some reports, which 
showed significiant increase in children and post-
menopausal  women,  Hou  MF  et  al.9  found  that 
there was no significiant relationship between urine 
Dpd/Cre  ratios  and  the  menopausal  status.  This 
suggests that the bone destruction induced by the 
menopause is less than that caused by cancer me-
tastasis. This study also showed that there were no 
different values of uPYR, uDPD and sALP between 
postmenopausal healthy women and age-matched 
premenopausal women.
Unexpectedly some researchers found higher 
levels  of  uPYR  and  uDPD  in  breast  cancer  pa-
tients without bone metastases compared to con-
trol groups’ values.8,16,17,18 We have also obtained 
similar  results.  Despite  a  negative  radiological  or 
radioistopical  skeletal  survey,  there  are  different 
explanations about high levels of uPYD and uDPD 
in patients without metastatic bone disorders. First, 
the  invading  neoplastic  disease  might  directly  in-
duce  the  release  of  pyridinium  cross-links  from 
extraosseous tissue, such as tendons, cartilage or 
blood vessels. Thus, excretion in the urine of pirid-
inyum cross-links increased and urinary PYR / DPD 
ratio altered. Catabolic events associated with the 
neoplastic disease might stimulate bone resorption 
throughout the skeleton. This theory is supported by 
the fact that mediators of tumor cachexia, such as 
tumor necrosis factor-α and interleukin -1 and -6 are 
also considered potent stimulators of osteoclast ac-
tivity. Subclinical osteolysis could also contribute to 
the elevated levels of urinary crosslinks.8
Pecherstorfer et al.8 reported that from a group 
of  55  individuals  without  bone  metastasis  at  the 
beginning of the follow-up, only 2 of them had de-
veloped bone metastasis. We also followed our pa-
tients. After a 6-year follow-up of patients, 5.9% had 
died (n=2), 2.9% of those patients had local metas-
tasis (n=1), 2.9% had liver metastasis (n=1), 5.9% 
had lung metastasis (n=2) and 8.8% had bone me-
tastasis (n=3). 
The efficacy of uPYR, uDPD to discriminate be-
tween patients without neoplastic bone involvement 
and healthy group was assessed by ROC analysis. 
Pecherstorfer et al.8 found that the urinary pyridini-
um cross-links were obviously most effective in pre-
dicting the absence or evidence of metastatic bone 
disease.  They  identified  that  using  50  µmolPYR/ 
mol creatinine as the cut-off level, the sensitivity of 
uPYR to predict bone metastases was 88.7%, and 
the specificity was 41.8 %. Walls et al. showed that 
the sensitivity of uPYR was 80 %, the specificity 
was 93% by using 70 µmolPYR/ mol creatinine as 
the cut-off level.
We have demonstrated that the area under the 
ROC curve was 0.84 for uPYR, 0.79 for uDPD. So, 
the best diagnostic efficiency by comparing the area 
under the curve was provided by uPYR followed by 
uDPD and sALP. The cut off value, sensitivity and 
specificity of PYR were established 47.3 pmol/µmol 
creatinin, 82% and 80% respectively. The cut off 
value, sensitivity and specificity of uDPD were de-
termined 9.53 pmol/µmol creatinin, 76%, 72% re-
spectively. As mentioned above, because of the low 
specificity of uPYR was the release of pyridinium Z. Giniş et al. Urinary pyridinoline in breast cancer 424
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cross-links from extraosseous tissues after the inva-
sion and subclinical osteolysis.8 The higher sensitiv-
ity of uPYR was considered to be due to the fact 
that the concentration of uDPD was about a quarter 
that of uPYR, so that the error in measuring uDPD 
assay became larger.12
In conclusion, this study revealed that measure-
ment of uPYR and uDPD assays may contribute to 
the early detection of metastatic spread to bone in 
breast cancer patients. The high uPYR and uDPD 
level may be an early sign of occult metastases in 
patients with no bone metastasis assessed by scin-
tigraphic techniques.
Because survival after diagnosis of bone me-
tastases is relatively short for patients with breast 
tumors,  methods  are  needed  to  predict  skeletal 
complications in a shorter timescale than is possible 
with current imaging methods. From the results of 
our current study, the use of bone marker data may 
make a major contribution to this need by identify-
ing those patients at highest risk who warrant the 
highest priority for intervention to prevent skeletal 
complications.  But  longitudinal  studies  should  be 
performed  to  evaluate  whether  these  parameters 
might be useful in monitoring progression or remis-
sion of neoplastic bone disease.
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